Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Papilloma 1Ototoxicity 1Hearing Loss 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Hyaluronic Acid × Clear all
NCT04262336 2023-07-06

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Decibel Therapeutics

Phase 1 Completed
22 enrolled

Ototoxicity, Hearing Loss

NCT05625308 2022-12-22

Effect of Natural Compounds on the Severity of HPV-induced Cervical Lesions

Lo.Li.Pharma s.r.l

Phase NA Completed
40 enrolled

Papilloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡